Aspira Women’s Health (NASDAQ:AWH) Now Covered by StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research report issued on Saturday. The firm set a “hold” rating on the stock.

Separately, Alliance Global Partners lowered their target price on shares of Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating for the company in a research note on Wednesday, August 14th.

Aspira Women’s Health Price Performance

Shares of NASDAQ AWH opened at $0.75 on Friday. The company has a market capitalization of $12.50 million, a P/E ratio of -0.62 and a beta of 1.39. The company has a 50 day simple moving average of $0.84 and a 200-day simple moving average of $1.17. Aspira Women’s Health has a 1 year low of $0.67 and a 1 year high of $5.65.

Hedge Funds Weigh In On Aspira Women’s Health

An institutional investor recently bought a new position in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co acquired a new position in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned 0.19% of Aspira Women’s Health at the end of the most recent quarter. 12.19% of the stock is owned by institutional investors and hedge funds.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.